Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mol Cell Neurosci. 2011 Jan;46(1):89-100. doi: 10.1016/j.mcn.2010.08.009. Epub 2010 Aug 27.

Neurostatin blocks glioma cell cycle progression by inhibiting EGFR activation.

Author information

  • 1Neural Plasticity Group, Functional and Systems Neurobiology Department, Cajal Institute, CSIC, 28002 Madrid, Spain.

Abstract

The high frequency and malignancy of human glioblastomas has stimulated the search for potential therapeutic approaches. The control of the glioma cell proliferation in response to mitogenic signals is one of the most promising antitumoral strategies, and the main target of several therapies. Neurostatin, an O-acetylated derivative of the ganglioside GD1b, has potent antiproliferative activity over the in vitro and in vivo growth of glioma cells. The mechanism of its antitumoral action is the focus of the present study. Using a combined in vitro-in vivo approach, we observed that neurostatin arrested glioma proliferation by inhibiting the expression of cell cycle promoters (i.e. cyclins and CDKs) and promoting the expression of cell cycle inhibitors (i.e. p21 and p27). Neurostatin inhibits epidermal growth factor receptor (EGFR) signaling pathways, blocking the activation of the main promitogenic MAPKs and PI3K pathways. Neurostatin action not only interferes in the cell cycle progression, but also in the protection from apoptosis, and the generation of angiogenic and invasive responses. The antitumoral actions described here point to neurostatin as a novel and promising chemotherapeutic agent for glioma treatment.

Copyright © 2010. Published by Elsevier Inc.

PMID:
20801220
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk